AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30696677 — intervention group
Group type: COMPARATOR
Intervention: Screw-distraction group
Number of subjects: 70
Study 29768348 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflection flexible visual gastric tube
Number of subjects: 20
Study 29768348 — intervention group
Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20
Study 27442715 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg)
Number of subjects: 41
Study 27442715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 24554104 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous haematopoietic stem cell transplantation (HSCT)
Number of subjects: 48
Study 22901308 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 1600 mg
Number of subjects: 120
Study 22901308 — intervention group
Group type: EXPERIMENTAL
Intervention: SAMe 800 mg
Number of subjects: 120
Study 22901308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20003969 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-knife sphincterotomy (NKS)
Number of subjects: 732
Study 20003969 — intervention group
Group type: COMPARATOR
Intervention: No NKS (Control)
Number of subjects: 732
Study 20003969 — intervention group
Group type: EXPERIMENTAL
Intervention: NKS
Number of subjects: 732
Study 20003969 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempts at cannulating the papilla
Number of subjects: 732
Study 17639099 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial approach for PCI using abciximab
Number of subjects: 114
Study 17639099 — intervention group
Group type: COMPARATOR
Intervention: Femoral approach for PCI using abciximab
Number of subjects: 114
Study 17639099 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 114
Study 15887009 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib 20 mg single dose on day 1 and 20 mg twice daily on days 4-7, followed by a single morning dose on day 8.
Number of subjects: 25
Study 12492725 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine, 5 mg once daily
Number of subjects: 190
Study 12492725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 9799756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic or continuous hormone replacement therapy (HRT) with an estrogen analog (tibolone)
Number of subjects: 0
Study 9799756 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate (ibandronate)
Number of subjects: 0
Study 9799756 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum CrossLaps One Step ELISA
Number of subjects: 0
Study 9799756 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine CrossLaps ELISA
Number of subjects: 0
Study 9799756 — intervention group
Group type: COMPARATOR
Intervention: Serum CrossLaps One Step ELISA vs Urine CrossLaps ELISA
Number of subjects: 0
Study 8557555 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU length of stay
Number of subjects: 45
Study 8557555 — intervention group
Group type: EXPERIMENTAL
Intervention: Total hospital length of stay
Number of subjects: 45
Study 8557555 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional status at 6-month follow-up
Number of subjects: 45
Study 2199209 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled frusemide (approximately 28 mg)
Number of subjects: 12
Study 189724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride orally
Number of subjects: 0
Study 189724 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluphenazine decanoate
Number of subjects: 0
Study 189724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31502640 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Dry Needling (DDN)
Number of subjects: 34
Study 31502640 — intervention group
Group type: COMPARATOR
Intervention: Ischemic Compression (ICT)
Number of subjects: 34
Study 29806557 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with hypertension (n=219)
Number of subjects: 330
Study 29806557 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals (BMI ≥30 kg/m2)
Number of subjects: 330
Study 29806557 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with hypertension
Number of subjects: 330
Study 28588021 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate
Number of subjects: 110
Study 28588021 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25881936 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 9572
Study 25881936 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg/day
Number of subjects: 9572
Study 25881936 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C variability (by ASV)
Number of subjects: 9572
Study 23689947 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH (tesamorelin, 1 mg/d)
Number of subjects: 30
Study 21926261 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan for 1 year
Number of subjects: 340
Study 18483726 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (5 mg/day after an induction period of 3 mg/day for 2 weeks)
Number of subjects: 15
Study 15969845 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive intervention study
Number of subjects: 0
Study 11951094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily
Number of subjects: 394
Study 11951094 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 50 mg twice daily
Number of subjects: 394
Study 11951094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394
Study 9794344 — intervention group
Group type: EXPERIMENTAL
Intervention: QoL collected before randomization
Number of subjects: 200
Study 9794344 — intervention group
Group type: COMPARATOR
Intervention: QoL collected after randomization
Number of subjects: 200
Study 7885426 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 micrograms)
Number of subjects: 270
Study 7885426 — intervention group
Group type: COMPARATOR
Intervention: Oral misoprostol (800 micrograms)
Number of subjects: 270
Study 2198211 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg sultamicillin (STM) b.i.d.
Number of subjects: 132
Study 2198211 — intervention group
Group type: COMPARATOR
Intervention: 625 mg amoxicillin/clavulanate (AMX/CLA) t.i.d.
Number of subjects: 132
Study 333869 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium clofibrate (2 g)
Number of subjects: 0
Study 333869 — intervention group
Group type: COMPARATOR
Intervention: Cholestyramine (12 g)
Number of subjects: 0
Study 333869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of calcium clofibrate and calcium carbonate (2 + 2 g)
Number of subjects: 0
Study 31600031 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric heating pad (40°C) applied for 10 minutes before IV insertion
Number of subjects: 84
Study 31600031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heating pad)
Number of subjects: 84
Study 31129484 — intervention group
Group type: EXPERIMENTAL
Intervention: Dosed Exercise Intervention (DEI)
Number of subjects: 302
Study 31129484 — intervention group
Group type: COMPARATOR
Intervention: Health Education Intervention (HEI)
Number of subjects: 302
Study 28012035 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib (4-week treatment prior to surgery)
Number of subjects: 20
Study 28012035 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4-week treatment prior to surgery)
Number of subjects: 20
Study 25359924 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN-α) antiviral therapy
Number of subjects: 91
Study 24018224 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 70
Study 24018224 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 70
Study 21813054 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Visual Analogue Scale (VAS)
Number of subjects: 1121
Study 19786646 — intervention group
Group type: EXPERIMENTAL
Intervention: Sesame supplementation (25 g/d of sesame, approximately 50 mg/d of sesame lignan)
Number of subjects: 33
Study 19786646 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric matched control
Number of subjects: 33
Study 16764130 — intervention group
Group type: EXPERIMENTAL
Intervention: WMTA
Number of subjects: 48
Study 16764130 — intervention group
Group type: COMPARATOR
Intervention: CH
Number of subjects: 48
Study 15182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.05 mg/kg)
Number of subjects: 13
Study 15182126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 15182126 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 13
Study 11429668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) in combination with clarithromycin for 14 days
Number of subjects: 0
Study 11429668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate (RBC) used alone or in combination with other antibiotics
Number of subjects: 0
Study 11429668 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy with a proton pump inhibitor, clarithromycin and either amoxicillin or a nitroimidazole (tinidazole or metronidazole)
Number of subjects: 0
Study 11429668 — intervention group
Group type: EXPERIMENTAL
Intervention: Analogous regimens with RBC in place of proton pump inhibitors
Number of subjects: 0
Study 9099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet rich in fruits, vegetables, and low-fat dairy products
Number of subjects: 459
Study 9099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruits-and-vegetables diet
Number of subjects: 459
Study 9099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (hypertensive subjects)
Number of subjects: 459
Study 9099655 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination diet (non-hypertensive subjects)
Number of subjects: 459
Study 9099655 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study 8058249 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal prenatal screening and selective intrapartum chemoprophylaxis
Number of subjects: 0
Study 8058249 — intervention group
Group type: COMPARATOR
Intervention: Selective intrapartum chemoprophylaxis based on clinical risk factors
Number of subjects: 0
Study 2854762 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion (5 mg bolus + 2.1 mg/h for 7 h)
Number of subjects: 2
Study 2854762 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (10 mg twice daily for 6 weeks)
Number of subjects: 2
Study 2854762 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (NAL) infusion after tamoxifen administration
Number of subjects: 2
Study 30111294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.05 mg/kg (group O1)
Number of subjects: 215
Study 30111294 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 0.1 mg/kg (group O2)
Number of subjects: 215
Study 30111294 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (group NS)
Number of subjects: 215
Study 27625082 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg per day)
Number of subjects: 116
Study 27625082 — intervention group
Group type: COMPARATOR
Intervention: Control (no olmesartan)
Number of subjects: 116
Study 25547319 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education program (DVD)
Number of subjects: 94
Study 25547319 — intervention group
Group type: COMPARATOR
Intervention: Newborn nutrition education program (DVD)
Number of subjects: 94
Study 23915144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline physical performance assessment (knee-extension strength, one-legged standing time, walking speed)
Number of subjects: 42
Study 23915144 — intervention group
Group type: EXPERIMENTAL
Intervention: One-legged standing time (sec)
Number of subjects: 42
Study 23915144 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gray matter volume (voxel-based morphometry)
Number of subjects: 42
Study 20533438 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 40
Study 18316463 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential data monitoring for efficacy
Number of subjects: 0
Study 15310784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, epirubicin, and fluorouracil
Number of subjects: 448
Study 15310784 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin, cyclophosphamide, and granulocyte colony-stimulating factor
Number of subjects: 448
Study 11575532 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia with propofol
Number of subjects: 2010
Study 11575532 — intervention group
Group type: COMPARATOR
Intervention: Inhalational anesthesia with isoflurane-nitrous oxide
Number of subjects: 2010
Study 9576425 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 to 40 mg once daily
Number of subjects: 4444
Study 9576425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4444
Study 9576425 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 4444
Study 7872726 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose gestagen treatment (500 mg MPA i.m. twice weekly for three months)
Number of subjects: 82
Study 7872726 — intervention group
Group type: COMPARATOR
Intervention: Control group (previous report with abrasio only)
Number of subjects: 82
Study 3124432 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dosage of cytosine arabinoside (3mg/m2/twice daily)
Number of subjects: 38
Study 3124432 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low dosage of cytosine arabinoside (3mg/m2/twice daily) with androgens
Number of subjects: 38
Study 30327912 — intervention group
Group type: EXPERIMENTAL
Intervention: Transection of the hernial sac
Number of subjects: 159
Study 30327912 — intervention group
Group type: COMPARATOR
Intervention: Complete dissection of the hernial sac
Number of subjects: 159
Study 30282393 — intervention group
Group type: COMPARATOR
Intervention: Intraarticular methylprednisolone injection
Number of subjects: 30
Study 30282393 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed radiofrequency ablation
Number of subjects: 30
Study 26692193 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐453859 (400 mg once daily or 100 mg twice daily)
Number of subjects: 0
Study 26692193 — intervention group
Group type: EXPERIMENTAL
Intervention: Setipiprant (not specified dosage)
Number of subjects: 0
Study 26692193 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT‐453859 and its active metabolite ACT‐463036 (combined concentration)
Number of subjects: 0
Study 25283715 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation (TAVI)
Number of subjects: 87
Study 25283715 — intervention group
Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 87
Study 25283715 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 87
Study 22421745 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL) 400 mg + Atazanavir (ATV) 300 mg twice daily for 4 weeks followed by RAL 800 mg + ATV/ritonavir 300/100 mg once daily for 4 weeks
Number of subjects: 25
Study 20134307 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal strength training and conventional rehabilitation
Number of subjects: 24
Study 20134307 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation only
Number of subjects: 24
Study 17290336 — intervention group
Group type: EXPERIMENTAL
Intervention: Writing about stressful events (18 patients)
Number of subjects: 32
Study 17290336 — intervention group
Group type: COMPARATOR
Intervention: Writing about trivial topics (14 patients)
Number of subjects: 32
Study 16274368 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (ergocalciferol, initially 10,000 IU weekly then 1,000 IU daily)
Number of subjects: 625
Study 16274368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 625
Study 11354390 — intervention group
Group type: COMPARATOR
Intervention: 500 mg IR clarithromycin tablets twice daily for 7 days (AECB) or 14 days (AMS)
Number of subjects: 0
Study 11354390 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg (2 x 500 mg) ER clarithromycin tablets once daily for 7 days (AECB) or 14 days (AMS)
Number of subjects: 0
Study 9130152 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum passive inversion range of motion
Number of subjects: 30
Study 9130152 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak passive resistive torque
Number of subjects: 30
Study 7708453 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline flush (Group I, n = 68)
Number of subjects: 126
Study 7708453 — intervention group
Group type: COMPARATOR
Intervention: Saline flush (Group II, n = 58)
Number of subjects: 126
Study 3308731 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil, 600 mg daily for 4 weeks
Number of subjects: 10
Study 3308731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31448953 — intervention group
Group type: EXPERIMENTAL
Intervention: Grand Veggie (vegetarian burger)
Number of subjects: 1126
Study 31448953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian labeled burger
Number of subjects: 1126
Study 31448953 — intervention group
Group type: COMPARATOR
Intervention: Control group (Big Mac)
Number of subjects: 1126
Study 31448953 — intervention group
Group type: COMPARATOR
Intervention: Control group (meat-based burger)
Number of subjects: 1126
Study 30704289 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroanatomic mapping-guided low fluoroscopy PHBP (group 1)
Number of subjects: 30
Study 30704289 — intervention group
Group type: COMPARATOR
Intervention: Conventional fluoroscopy guided PHBP (group 2)
Number of subjects: 30
Study 28284473 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Expiratory Pressure (PEP) therapy
Number of subjects: 52
Study 28284473 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (control)
Number of subjects: 52
Study 25218610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone/Naloxone prolonged-release (OXN PR)
Number of subjects: 128
Study 25218610 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone prolonged-release (OxyPR)
Number of subjects: 128
Study 22476513 — intervention group
Group type: EXPERIMENTAL
Intervention: QAE-P questionnaire
Number of subjects: 708
Study 22476513 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital variables (open vs closed ward, disorder-specific organization, number of patients under German Mental Health Act)
Number of subjects: 708
Study 21099399 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrology Now e-mail alert service
Number of subjects: 1683
Study 21099399 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1683
Study 20011858 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural block (ACa)
Number of subjects: 118
Study 20011858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic and femoral block (IF)
Number of subjects: 118
Study 20011858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic and saphenous block (IS)
Number of subjects: 118
Study 20011858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sciatic block and local anesthesia (IL)
Number of subjects: 118
Study 20011858 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 118
Study 16955243 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine (1.25 mg, 2.5 mg, 5 mg)
Number of subjects: 24
Study 16955243 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (10 mg)
Number of subjects: 24
Study 16955243 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Number of subjects: 24
Study 16955243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 15070939 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise
Number of subjects: 34
Study 15070939 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 34
Study 11320783 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9296891 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser Doppler Flowmetry in IDDM patients with peripheral neuropathy
Number of subjects: 30
Study 8514070 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of lidocaine spray
Number of subjects: 158
Study 8514070 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 158
Study 30506630 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunosuppression withdrawal
Number of subjects: 275
Study 30506630 — intervention group
Group type: COMPARATOR
Intervention: Maintenance immunosuppression
Number of subjects: 275
Study 29431520 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-resveratrol (300 mg)
Number of subjects: 24
Study 29431520 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 27611858 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA (SGLT2 inhibitor)
Number of subjects: 162
Study 27611858 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPA (SGLT2 inhibitor) + PPAR-γ inhibitor GW9662
Number of subjects: 162
Study 27611858 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 25281710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m2 i.v. on day 1 of a 21-day cycle)
Number of subjects: 161
Study 25281710 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (250 mg/day orally)
Number of subjects: 161
Study 25281710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 161
Study 25281710 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 161
Study 25281710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and Gefitinib
Number of subjects: 161
Study 25281710 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed (in patients with EGFR mutation)
Number of subjects: 161
Study 25281710 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib (in patients with EGFR mutation)
Number of subjects: 161
Study 22902793 — intervention group
Group type: EXPERIMENTAL
Intervention: TAP block with bupivacaine
Number of subjects: 46
Study 22902793 — intervention group
Group type: COMPARATOR
Intervention: Control (saline placebo)
Number of subjects: 46